In an attempt to shed light on the mechanistic link between IDH mutations and oncometabolic adaptations, we profiled the in vivo metabolic content of patient‐derived glioma xenografts and clinical glioma samples with or without the IDH mutation. Here, IDH1 is linked to glioma.